Trade Summary

1 week ago, Venker Eric, serving as Pres, Immunovant CEO at Roivant Sciences Ltd. (ROIV), sold 275,000 shares at $22.47 per share, for a total transaction value of $6,179,750.00. Following this transaction, Venker Eric now holds 1,654,597 shares of ROIV.

This sale represents a 14.00% decrease in Venker Eric's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Tuesday, December 23, 2025 and publicly disclosed via SEC Form 4 filing on Monday, December 29, 2025, 6 days after the trade was made.

Roivant Sciences Ltd. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.